Xeris Biopharma CFO Steven Pieper sells $42,500 in shares
On September 1, 2026, Xeris Biopharma Holdings, Inc.'s Chief Financial Officer Steven Pieper sold 5,000 shares of the company's common stock for a total of $42,500. The transaction was conducted under a Rule 10b5-1 trading plan adopted by Mr. Pieper on August 18, 2025. Currently, Mr. Pieper still holds 1,356,053 shares of Xeris Biopharma common stock.
Xeris Biopharma shares have seen a 38% return over the past six months, according to InvestingPro data, but the current stock price of $8.43 may be considered overvalued by the platform. In their recent second-quarter 2026 financial results, Xeris Biopharma reported $92.1 million in revenue, surpassing analyst estimates, but also posted a loss of $0.18 per share, missing a projected profit of $0.01.
The company's strong commercial momentum, driven by high demand for RECORLEV and rebounding sales of Gvoke, was noted, yet profitability challenges persist due to a one-time non-cash GAAP charge from convertible note remeasurement.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
